

Endocrine disruptors – where are we


Biocides Stakeholders' Day

26 September 2017


Simón Gutiérrez Alonso Biocides Assessment Unit, ECHA


























Drafting team and consultation group



Drafting team: ECHA, EFSA, JRC

ECHA ED expert group Consultation group

Member State pesticide experts


& other stakeholders



Guidance timelines









Expected impact on different processes

Active substances under evaluation

- COM note
- March 2017 competent authorities meeting

Biocidal products

- COM note
- July 2017 competent authorities meeting

Active substances already approved


 Note to be prepared by COM



Procedure for active substances

ACTIVE SUBSTANCES (≈300)

ACTIVE SUBSTANCE/PRODUCT-TYPE (≈600)





Commission note on ongoing evaluations

- Refers to draft delegated act: criteria applicable 6 months after entry into force
- Distinction between dossiers before/after 1 Sept 2013
- Exclusion and substitution criteria depends on HH or ENV
- All BPC opinions will need to have ED properties assessed according to the new criteria
- Opinion is adopted but no decision at the Standing Committee → COM return opinion to ECHA
- Cooperation ECHA-EFSA







Notes for applicants




12

- Delays are foreseen in the process
 - 45 active substances maybe on hold pending additional data
 - Limited experience of all parties
 - Additional information may be needed, possibly iteratively
- Start reviewing the data available and engage in discussions with evaluating authority
- Consider the guidance (when available)
- Plan resources and expertise to support your active substances

echa.europa.eu



Procedure for products



Name	Function	CAS no.	Content (%)
AS 1	Active substance	12345	15
AS 2	Active substance	45678	10
Non-AS 1	Surfactant	123455	15
Non-AS 2	Solvent	123456	45
Pigment 1	Pigment	123457	10
Perfume 1	Perfume	123458	5



Commission note on products (1/3)

- ED criteria also to non-active substances (socalled "co-formulants")
- A product is ED if it contains an active substance and/or non-active substance(s) with ED properties
- Member State authorities can request additional information but should respect the overall 3-year deadline laid down in BPR



Commission note on products (2/3)

- Substances also under REACH. To avoid work duplication and ensure consistency, the evaluating body:
 - Checks whether the potential ED properties of the coformulant already have been or are assessed under REACH (e.g. substance evaluation or SVHC identification)
 - If not, consider triggering evaluation with the Member State responsible for REACH
 - If running in parallel, the regulatory consequences do not apply





Commission note on products (3/3)


- For products where the evaluation has finalised but the product is not yet authorised, Member State competent authority may still request further information if needed
- For already authorised products, the BPR sets the rules to amend or cancel an authorisation





Observations from ECHA

- Information on co-formulants is limited
- Data ownership
- Evaluation of co-formulants may challenge the deadlines





Notes for applicants



- Review the co-formulants you use in your products
- Start discussing with the substance suppliers in relation to data available or on-going regulatory processes (e.g. under REACH)
- Contact your Member State authority to discuss your case
- Plan resources and expertise to support your products

echa.europa.eu 18




Procedure for already approved active substances

- Approx. 130 active substances already approved
- Additional information may be needed
- If evaluation needed before renewal, a specific work programme has to be put in place; discussions between COM and ECHA on-going



Sorting substances for assessment



echa.europa.eu

20



Observations from ECHA

- Need to start ASAP to sort and evaluate (high time pressure)
- Additional resources needed
 - Sorting the substances
 - Coordination activities
 - Evaluation stage by IND and MSCAs
 - Impact on BPC-WG and ED-EG





Notes for applicants



- Contact the evaluating competent authority for the active substance if new information is available
- Plan resources and expertise to support your already approved active substances

22







Take home messages



- The application of the new ED criteria will have an impact on timelines and resources for industry, MSCAs and ECHA
- Industry should consider the scientific guidance when available
- Industry and Member State competent authorities should start reviewing the data available
- Be aware that co-formulants should also be considered for ED properties

ECHA.EUROPA.EU



Links

Information on actual guidance development status

https://echa.europa.eu/chemicals-in-our-life/hot-topics/endocrine-disruptors

 Outline of Draft Guidance Document for the Implementation of the Hazard-based Criteria to Identify Endocrine Disruptors

https://echa.europa.eu/documents/10162/22879598/Endocrine+guidance+outline/64736dc0-0549-9fc8-d031-151aa76f2137

Endocrine disruptor expert group

https://echa.europa.eu/addressing-chemicals-of-concern/substances-of-potential-concern/endocrine-disruptor-expert-group

EU COM on Endocrine disruptors

https://ec.europa.eu/health/endocrine_disruptors/next_steps_en

echa.europa.eu

25



Thank you

simon.gutierrez(at)echa.europa.eu

Follow our news

Newsletter: echa.europa.eu/subscribe

Twitter: @EU_ECHA Facebook: @EUECHA

LinkedIn: European Chemicals Agency

YouTube: EUchemicals

